

# CITATION REPORT

List of articles citing

## Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future

DOI: 10.1007/s13555-018-0230-9  
Dermatology and Therapy, 2018, 8, 173-194.

**Source:** <https://exaly.com/paper-pdf/69382761/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model. <i>Experimental and Therapeutic Medicine</i> , <b>2019</b> , 17, 1030-1038	2.1	6
39	Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , <b>2018</b> , 19, 907-918	7.1	21
38	Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. <i>Therapeutics and Clinical Risk Management</i> , <b>2018</b> , 14, 1489-1497	2.9	9
37	Biosimilars for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 993-1000	5.4	18
36	Efficacy of Biosimilars in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 67-69	1.1	1
35	Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. <i>Clinical, Cosmetic and Investigational Dermatology</i> , <b>2019</b> , 12, 311-321	2.9	12
34	The future landscape of biosimilars in rheumatology: Where we are where we are going. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 203-208	13.6	4
33	Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 962-969	6.1	18
32	PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3. <i>Biomedicine and Pharmacotherapy</i> , <b>2019</b> , 110, 265-274	7.5	11
31	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 794-800	2.8	15
30	AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 316-326	4	22
29	Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 123, 109747	7.5	15
28	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifiliográficas</i> , <b>2020</b> , 111, 809-814	0.5	2
27	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifiliográficas</i> , <b>2020</b> , 111, 809-814	0.5	
26	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 1121-1135	4	1
25	Safety and efficacy of Chinese herbal bath for psoriasis vulgaris: A protocol for systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2020</b> , 99, e20488	1.8	
24	Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 459-466	4.1	3

23	Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 483-491	7.1	9
22	The Use of TNF- $\alpha$ Inhibitors in Treating Pediatric Skin Disorders. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 311-319	4.2	6
21	A case of pediatric acrodermatitis continua of Hallopeau successfully treated with adalimumab biosimilar. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13327	2.2	1
20	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 87-96	5.4	2
19	Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single Center study. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-9	2.8	0
18	Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 1620-1641	8.8	7
17	Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
16	Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies. <i>European Journal of Pharmacology</i> , <b>2021</b> , 907, 174254	5.3	3
15	TNF- $\alpha$ inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 591-598	5.1	7
14	Reinforcing involvement of NK cells in psoriasiform dermatitis animal model. <i>Experimental and Therapeutic Medicine</i> , <b>2019</b> , 18, 4956-4966	2.1	2
13	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. <i>JAAD International</i> , <b>2020</b> , 1, 224-230	0.9	0
12	Biosimilars for Psoriasis. <b>2021</b> , 279-289		
11	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.. <i>Ophthalmology and Therapy</i> , <b>2022</b> ,	5	1
10	Biosimilars. <i>Turkderm</i> , 75-76	2	
9	Production of an anti-TNF- $\alpha$ antibody in murine myeloma cells by perfusion culture. <i>Applied Microbiology and Biotechnology</i> ,	5.7	
8	Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?. <i>European Journal of Pharmacology</i> , <b>2022</b> , 929, 175147	5.3	0
7	Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis.		
6	Adalimumab Biosimilar Efficacy and Safety in a 5-Year-Old Patient with Severe Plaque Psoriasis During SARS-CoV-2 Pandemic Outbreak. <b>2022</b> , 10, 257-260		0

- 5 Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. ○
- 4 Real-World Outcomes Following Switching from Anti-TNF Reference Products to Biosimilars for the Treatment of Psoriasis. 1-29 ○
- 3 Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. 11, 1178 ○
- 2 Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. 11, 1178 ○
- 1 Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. **2023**, 55, 1335-1345 ○